Multi-modal Imaging of Myofascial Pain

Purpose

The goal of this study is to develop new imaging biomarkers for quantitative assessments of myofascial pain.

Condition

  • Myofascial Pain

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  1. Absence of a history of chronic pain in the targeted anatomical location (i.e., neck and shoulder) that had limited activities of daily living or work 2. A numerical current pain index of lower than 0.5 according to initial assessment with visual analog scale 3. Able to understand the goal of the project and give informed consent. Healthy Volunteer

Exclusion Criteria

  1. Pregnancy or breastfeeding 2. Contraindication to MRI 3. Previous severe/acute neck or shoulder injury 4. Previous neck or shoulder surgery 5. Neck or shoulder deformities 6. Inability to provide consent. Myofascial Pain Patient Inclusion Criteria: 1. Between the ages of 18 and 80 years old 2. Neck and/or shoulder pain, unilateral or bilateral 3. Duration of symptoms for longer than 4 weeks 4. Pain scale at the active state higher than 4 according to initial assessment with visual analog scale 5. Presence of active trigger point(s) according to palpation and/or presence of taut band Myofascial Pain Patient Exclusion Criteria: 1. Recent history of trauma to the neck (e.g., whiplash) 2. Acute cervical radiculopathy 3. Acute cervical spine pain component or acute cervical spinal pathology Presence of neuromuscular pathologies or inflammatory muscle diseases (e.g., dermatomyositis) 4. Systemic disease with diffuse body pain (e.g., system lupus erythematosus and and thyroid disease) 5. Peripheral neuropathy 6. Cancer-related pain 7. Pregnancy, coagulopathy, fever, general/local infection at the pain site, substance abuse, peripheral neuropathy, or any other diseases that may account for signs and symptoms mimicking myofascial pain 8. Contraindication to MRI.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
This is a two-phase, NIH-supported study. The first R61 phase (currently awarded) is an observational study with one control group and one patient group. The second R33 phase is a randomized clinical trial, which will be awarded by the end of the R61 phase. The study design provided here is for R61 only.
Primary Purpose
Diagnostic
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Multi-modal imaging of myofascial pain
Participants with and without myofascial-related pain disease will receive multi-modal, multi-parametric, multi-scale imaging, including magnetic resonance imaging, surface electromyography, and fiber-optic imaging and sensing.
  • Diagnostic Test: Multi-modal, multi-parametric, multiscale imaging of the myofascial unit
    Study Participants will undergo four study procedures at one visit, including magnetic resonance imaging (MRI), surface electromyography (sEMG), fiber-optic imaging and sensing, and questionnaires.

Recruiting Locations

Washington University in St. Louis and nearby locations

Washington University
St Louis 4407066, Missouri 4398678 63110
Contact:
Robin Haverman
314-747-1624
rlhaverman@wustl.edu

More Details

NCT ID
NCT06036524
Status
Recruiting
Sponsor
Washington University School of Medicine

Detailed Description

This study aims to develop a multi-modal, multi-parametric, multi-scale imaging of the human myofascial unit by combining magnetic resonance imaging (MRI), surface electromyography (sEMG), and fiber-optic imaging and sensing. Participants (half with active neck/shoulder/back pain, and half healthy controls) will be recruited from pain management clinics and Volunteer for Health, or will be referred by Dr. Xioabin Yi. They will undergo all three imaging techniques and complete a number of patient questionnaires over the course of a single study visit. The study team will then identify candidate biomarkers capable of differentiating between healthy (no myofascial pain) and those with active pain to target in a future clinical trial.